文献速递生殖医学

GnRH激动剂联合来曲唑治疗对反复种植失败女性的效果

Effect of GnRH agonist and letrozole treatment in women with recurrent implantation failure.
PubMed 文献 · Fertil Steril · 2019-05-24

该回顾性队列研究纳入523例不明原因反复种植失败且已失败两次囊胚移植的女性,比较未预处理、单用GnRH激动剂2个月、GnRH激动剂联合来曲唑60天三组的第三次冻融囊胚移植结局。联合组临床妊娠率和活产率均高于另两组,后两组间无差异。作者认为联合治疗可能改善后续周期的活产率。

要点

  • GnRH激动剂联合来曲唑组临床妊娠率63%,高于单用GnRH激动剂组42%和未预处理组40%(P<.0001)。
  • 联合组活产率56%,高于单用GnRH激动剂组36%和未预处理组34%(P<.0001)。
  • 未预处理组与单用GnRH激动剂组妊娠结局无差异。

核心结论

  • 在反复种植失败患者中,GnRH激动剂联合来曲唑治疗可能改善后续周期的活产率。
  • 作者推测该改善源于子宫内膜容受性改变或对未诊断子宫内膜异位症的治疗。

研究设计与样本

  • 回顾性队列研究,在大学附属生殖中心进行。
  • 共纳入523例不明原因反复种植失败、已失败两次囊胚移植后行第三次冻融囊胚移植的不孕女性,排除已知子宫内膜异位症者。
  • 204例未预处理,143例仅接受2个月GnRH激动剂(醋酸亮丙瑞林3.75 mg肌内注射,每月一次),176例接受GnRH激动剂联合芳香化酶抑制剂(来曲唑5 mg口服,每日一次,共60天)。

主要发现

  • 年龄、窦卵泡计数、基础FSH水平、不孕时长、既往妊娠和足月分娩史在三组间相似(P>.05)。
  • 临床妊娠率:GnRH激动剂联合来曲唑组63%,单用GnRH激动剂组42%,未预处理组40%(P<.0001)。
  • 活产率:GnRH激动剂联合来曲唑组56%,单用GnRH激动剂组36%,未预处理组34%(P<.0001)。
  • 未预处理组与单用GnRH激动剂组妊娠结局无差异。

临床怎么用

  • 原文未据此给出推荐。
  • 作者认为,对反复种植失败患者,GnRH激动剂联合来曲唑治疗可能改善后续周期的活产率。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the influence of dual suppression with the use of GnRH agonist plus aromatase inhibitor compared with suppression with the use of GnRH agonist alone or no suppression at all in patients with idiopathic recurrent implantation failure (RIF). DESIGN: Retrospective cohort study. SETTING: University-affiliated reproductive center. PATIENT(S): A total of 523 infertile women who failed two blastocyst transfers underwent a third frozen blastocyst transfer. Women with known endometriosis were excluded. INTERVENTION(S): A total of 204 subjects were not pretreated, 143 received 2 months of GnRH agonist (3.75 mg intramuscular leuprolide acetate monthly) only, and 176 received GnRH agonist and aromatase inhibitor (5 mg oral letrozole daily for 60 days). Demographic and stimulation information was collected and cycle outcomes reported. MAIN OUTCOME MEASURE(S): Clinical pregnancy rates. RESULT(S): Age, antral follicle count, basal FSH levels, duration of infertility, previous pregnancies, and full-term deliveries were similar (P>.05). Clinical pregnancy rates were higher among women who received GnRH agonist plus letrozole compared with women who received GnRH agonist only or women without pretreatment (63%, 42%, and 40%, respectively; P<.0001). Live birth rates were higher among women who received GnRH agonist plus letrozole compared with the other groups (56%, 36%, and 34%; P<.0001). No differences in pregnancy outcomes were noted between patients who did not receive pretreatment and those in the GnRH agonist only group. CONCLUSION(S): In patients with RIF, treatment with a GnRH agonist plus letrozole may improve live birth rates in subsequent cycles. We hypothesize that this improvement is due to alterations in the endometrium receptivity or treatment of undiagnosed endometriosis.

来源:Fertil Steril,查看原文。版权归原作者所有。

引用

  1. Steiner N, Shrem G, Tannus S, et al. Effect of GnRH agonist and letrozole treatment in women with recurrent implantation failure. Fertil Steril. 2019. PMID: 31133384. doi:10.1016/j.fertnstert.2019.03.021

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。